Board appointment adds proven medical device leadershipMINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20. “We are pleased to welcome Mr. Carrel to our Board of Directors,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forward to his guidance as we continue advancing Inspire therapy for the many patients affected by OSA.” Mr. Carrel has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC), an innovative cardiac device company, since November 2012. Under Mr. Carrel’s leadership, AtriCure has advanced a robust pipeline of novel products for the treatment of atrial fibrillation, left atrial appendage management and pain management. During his tenure, AtriCure has grown from $82 million in revenue in 2013 to $535 million in 2025 while helping more than one million patients. Previously, Mr. Carrel served as Chairman of the Board of Directors of Axonics, Inc. from 2019 through 2024, until its sale to Boston Scientific Corporation. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School of the University of Pennsylvania. “I am excited to join Inspire at this important stage in the Company’s growth,” said Mr. Carrel. “With the recent launch of the fifth-generation Inspire device, a compelling product pipeline and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.” About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@inspiresleep.com617-549-2443
Author: Ken Dropiewski
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter –
CIRCA Scientific Appoints Jack Darby as Chief Executive Officer to Accelerate Commercial Expansion of Cardiovascular Access Portfolio
Veteran cardiovascular medical device executive to lead Company’s next phase of growth as CIRCA builds a differentiated cardiovascular access portfolio; Lee Geist transitions to Chief Operating Officer ENGLEWOOD, Colo., July 24, 2026 /PRNewswire/ — CIRCA Scientific, Inc., a…
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
MIT spinout to accelerate product development and first-in-human studies of its magnetic robotic navigation platform designed to dramatically improve the s
Wellumio closes oversubscribed $9.75 million pre-Series A round to accelerate portable stroke imaging technology
Australian medtech investor Bioshore Ventures and US neurotechnology investor Jumpspace Ventures join Wellumio’s oversubscribed pre-Series A round in the final close, supporting the next phase of clinical validation and commercialisation WELLINGTON, New Zealand, July 24, 2026 – Wellumio, a New Zealand medical technology company developing Axana®, a portable brain imaging […]
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas
AtriCure Reports Second Quarter 2026 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu
Caristo Diagnostics Expands Executive Team, Naming David Vort Chief Commercial Officer and Chris Louk Chief Financial Officer
Appointments to scale adoption of Caristo’s AI-powered cardiovascular technologies globally OXFORD, England and STAMFORD, Conn., July 23, 2026 /PRNewswire/ — Caristo Diagnostics, a global leader in AI-powered technologies for cardiovascular disease, today announced two additions to its…
Sentante’s CE-marked robotic platform is building the data foundation for endovascular physical AI
Drive-side force sensing and a 1:1 motion-mimicking interface make every procedure a training-grade record of expert clinical skill KAUNAS, Lithuania, July 23, 2026 /PRNewswire/ — Sentante, the medical robotics company building a haptic, device-agnostic platform for remote vascular…
Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World’s First Fully Recoverable Self-Expanding Dry-Valve TAVR System
The PREVAILS study, now fully enrolled, marks a critical step toward simultaneous regulatory submissions in China and Europe for the next-generation TAVR system HANGZHOU, China, July 23, 2026 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (02500.HK) today announced that patient enrollment…



